Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in Australia [0.03%]
澳大利亚肌层浸润性膀胱癌的围手术期化疗应用及结果相关性研究
Alison Hiong,James Lynam,Andrew Weickhardt et al.
Alison Hiong et al.
Objectives: To explore Australian data on perioperative chemotherapy use and associated outcomes in muscle-invasive bladder cancer (MIBC). Subjects and me...
Is a second TUR necessary in patients with primary high-grade Ta NMIBC, particularly in the context of initial cases? [0.03%]
初级高分级Ta期NMIBC患者再次进行经尿道切除术的必要性，尤其是对于初始病例？
Satoki Abe,Hiroyuki Fujinami,Naoyuki Yamanaka et al.
Satoki Abe et al.
Objective: To evaluate the clinical significance of a second transurethral resection of the bladder tumour (TURBT) in patients with a primary high-grade (HG) Ta non-muscle invasive bladder cancer (NMIBC), specifically sel...
Association between insulin resistance and prostate volume: A 4-year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial [0.03%]
胰岛素抵抗与前列腺体积之间的关系：来自减少前列腺癌（REDUCE）试验的为期4年的分析
James P Daniels,Alexander Hernández-Tirado,James Mirocha et al.
James P Daniels et al.
Objectives: Most, but not all studies, suggest insulin resistance is associated with benign prostatic hyperplasia, but its impact on prostate volume (PV) changes over time remains unclear. We examined whether higher insul...
Kosuke Kojo,Masahiro Uchida,Kazumitsu Yamasaki et al.
Kosuke Kojo et al.
Life after radical cystectomy: A mixed-methods targeted review of patient-reported quality of life following bladder removal [0.03%]
膀胱切除术后的生存状况：一种患者报告的生活质量综合评价方法的靶向回顾研究
Ingolf Griebsch,Kristian Juul,Andrew Bottomley et al.
Ingolf Griebsch et al.
Background: Radical cystectomy (RC) is a life-altering surgery primarily used to treat muscle-invasive bladder cancer (MIBC) and, occasionally, high-risk non-muscle-invasive bladder cancer (NMIBC). While this procedure ca...
Potential gains from radical treatment of men with prostate cancer according to life expectancy [0.03%]
根据预期寿命评估前列腺癌患者根治性治疗的潜在益处
Sandra Irenaeus,Hans Garmo,Rolf Gedeborg et al.
Sandra Irenaeus et al.
Objectives: To investigate the impact of age and life expectancy on treatment decisions and its consequences for outcomes among men with intermediate and high-risk prostate cancer (PCa). ...
Ureteral stent symptoms: A systematic review and meta-analysis comparing the use of mirabegron and tamsulosin [0.03%]
系统回顾和荟萃分析：比较使用mirabegron与坦索罗辛的症状改善情况（英文）
Daniel Madarshahian,Abdulrasheed Habeeb,Nimeshan Chandra-Segaran et al.
Daniel Madarshahian et al.
Background: Ureteral stent insertion, crucial for managing ureteral obstructions, often results in stent-related symptoms (SRSs) adversely affecting patient quality of life. This meta-analysis compares the effectiveness o...
Development of a novel risk model to predict CRPC progression following IMRT: Implications for tailoring treatment intensity [0.03%]
开发一种新颖的风险模型以预测IMRT后CRPC进展：对定制治疗强度的启示
Takashi Ogata,Rihito Aizawa,Hiroyasu Abe et al.
Takashi Ogata et al.
Objectives: To develop a novel risk score (RS) model to predict the probability of progression to castration-resistant prostate cancer (PCa) (CRPC) after intensity-modulated radiation therapy (IMRT) for patients with high...
Acute kidney injury as a predictor of infectious complications after mini-PCNL [0.03%]
经皮肾镜取石术后急性肾损伤预测感染并发症的作用
Angelo Cormio,Daniele Castellani,Domenico De Palma et al.
Angelo Cormio et al.
Objective: To investigate the incidence, risk factors and clinical consequences of acute kidney injury (AKI) following mini-percutaneous nephrolithotomy (mini-PCNL), with particular focus on its association with postopera...
Correction to "Therapy de-escalation for testicular cancer (THERATEST): A multi-centre observational cohort feasibility study of de-escalation therapies for good prognosis stage II germ cell tumours" [0.03%]
对“睾丸癌的治疗减毒（THERATEST）：一项关于具有良好预后的II期生殖细胞肿瘤的减毒疗法的多中心观察队列可行性研究”的修正
[This corrects the article DOI: 10.1002/bco2.70057.]. © 2025 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU Internation...
Published Erratum
BJUI compass. 2025 Sep 7;6(9):e70071. DOI:10.1002/bco2.70071 2025